ZFYVE19

Summary

ZFYVE19 (zinc finger FYVE-type containing 19, HGNC:20758) is a protein-coding gene on chromosome 15q15.1, encoding Abscission/NoCut checkpoint regulator (Q96K21). Key regulator of abscission step in cytokinesis: part of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage.

Enables phosphatidylinositol-3-phosphate binding activity. Involved in midbody abscission; mitotic cytokinesis checkpoint signaling; and negative regulation of cytokinesis. Located in centrosome; cleavage furrow; and midbody. Implicated in progressive familial intrahepatic cholestasis.

Source: NCBI Gene 84936 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cholestasis, progressive familial intrahepatic, 9 (Strong, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 105 total — 6 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 15
• MANE Select transcript: NM_001077268

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20758
Approved symbol	ZFYVE19
Name	zinc finger FYVE-type containing 19
Location	15q15.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14840, ANCHR, MPFYVE
Ensembl gene	ENSG00000166140
Ensembl biotype	protein_coding
OMIM	619635
Entrez	84936

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 protein_coding, 4 nonsense_mediated_decay, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000299173, ENST00000336455, ENST00000355341, ENST00000560078, ENST00000561617, ENST00000561768, ENST00000563497, ENST00000563530, ENST00000564258, ENST00000566407, ENST00000566767, ENST00000567756, ENST00000568062, ENST00000569057, ENST00000570108, ENST00000570162

RefSeq mRNA: 4 — MANE Select: NM_001077268 NM_001077268, NM_001258420, NM_001258421, NM_032850

CCDS: CCDS42025, CCDS58353, CCDS58354, CCDS58355

Canonical transcript exons

ENST00000355341 — 11 exons

Exon	Start	End
ENSE00001402271	40807089	40807868
ENSE00003488062	40813713	40813811
ENSE00003507950	40809408	40809458
ENSE00003528556	40809852	40809970
ENSE00003615397	40813338	40813417
ENSE00003638377	40813943	40814070
ENSE00003639833	40809119	40809240
ENSE00003663650	40810649	40810757
ENSE00003668027	40810071	40810216
ENSE00003741525	40814148	40815084
ENSE00003788632	40812699	40812902

Expression profiles

Bgee: expression breadth ubiquitous, 211 present calls, max score 95.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.5601 / max 80.7556, expressed in 1798 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146133	6.2242	1773
146134	3.1841	1395
146135	1.9393	1167
146136	0.2125	98

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	95.81	gold quality
mucosa of transverse colon	UBERON:0004991	93.91	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.85	gold quality
granulocyte	CL:0000094	93.36	gold quality
apex of heart	UBERON:0002098	93.15	gold quality
right lobe of liver	UBERON:0001114	92.37	gold quality
minor salivary gland	UBERON:0001830	91.15	gold quality
spinal cord	UBERON:0002240	91.03	gold quality
esophagus mucosa	UBERON:0002469	90.66	gold quality
metanephros cortex	UBERON:0010533	90.66	gold quality
right uterine tube	UBERON:0001302	90.55	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.37	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.19	gold quality
cerebellar hemisphere	UBERON:0002245	90.10	gold quality
cerebellar cortex	UBERON:0002129	89.92	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.89	gold quality
gall bladder	UBERON:0002110	89.62	gold quality
transverse colon	UBERON:0001157	89.59	gold quality
right frontal lobe	UBERON:0002810	89.21	gold quality
endocervix	UBERON:0000458	88.91	gold quality
esophagus	UBERON:0001043	88.76	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.67	gold quality
body of stomach	UBERON:0001161	88.59	gold quality
prefrontal cortex	UBERON:0000451	88.57	gold quality
stromal cell of endometrium	CL:0002255	88.53	gold quality
skin of abdomen	UBERON:0001416	88.51	gold quality
muscle layer of sigmoid colon	UBERON:0035805	88.47	gold quality
vermiform appendix	UBERON:0001154	88.32	gold quality
small intestine	UBERON:0002108	88.32	gold quality
right ovary	UBERON:0002118	88.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

4 targeting ZFYVE19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7151-5P	99.37	67.82	613
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-1-5P	98.70	68.66	1017
HSA-MIR-6811-3P	98.62	66.54	944

Literature-anchored findings (GeneRIF, showing 4)

• In a transcript from a patient with AML-M2, MLL is fused to a novel gene: MLL partner containing FYVE domain (MPFYVE). MPFYVE is also located on chromosome 15, about 170 kb telomeric to AF15q14. MPFYVE contains the highly conserved FYVE domain. [MPFYVE] (PMID:12618766)
• Propose that the abscission checkpoint is mediated by ANCHR and CHMP4C through retention of VPS4 at the midbody ring. (PMID:24814515)
• Biallelic loss-of-function ZFYVE19 mutations are associated with congenital hepatic fibrosis, sclerosing cholangiopathy and high-GGT cholestasis. (PMID:32737136)
• ZFYVE19 deficiency: a ciliopathy involving failure of cell division, with cell death. (PMID:38816193)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zfyve19	ENSDARG00000003642
mus_musculus	Zfyve19	ENSMUSG00000068580
rattus_norvegicus	Zfyve19	ENSRNOG00000012528
drosophila_melanogaster	CG6051	FBGN0039492
caenorhabditis_elegans		WBGENE00003084

Paralogs (13): RUFY3 (ENSG00000018189), ZFYVE16 (ENSG00000039319), SNX29 (ENSG00000048471), ZFYVE26 (ENSG00000072121), RUNDC3B (ENSG00000105784), RUNDC3A (ENSG00000108309), PLEKHM2 (ENSG00000116786), ZFYVE28 (ENSG00000159733), ZFYVE1 (ENSG00000165861), PLEKHF1 (ENSG00000166289), PLEKHF2 (ENSG00000175895), RUFY1 (ENSG00000176783), RUFY2 (ENSG00000204130)

Protein

Protein identifiers

Abscission/NoCut checkpoint regulator — Q96K21 (reviewed: Q96K21)

Alternative names: MLL partner containing FYVE domain, Zinc finger FYVE domain-containing protein 19

All UniProt accessions (9): Q96K21, H3BN64, H3BP54, H3BRF9, H3BRM1, H3BS07, H3BSF5, H3BUW6, H3BVF5

UniProt curated annotations — full annotation on UniProt →

Function. Key regulator of abscission step in cytokinesis: part of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage. Together with CHMP4C, required to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ZFYVE19/ANCHR and VPS4 and subsequent abscission.

Subunit / interactions. Interacts (via MIM1-B) with VPS4A; interaction takes place at the midbody ring following cytokinesis checkpoint activation.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Cleavage furrow. Midbody. Midbody ring.

Tissue specificity. Detected in brain, heart, skeletal muscle and kidney. Expressed in the liver (at protein level).

Post-translational modifications. Phosphorylated in vitro at Ser-22 by AURKB; however, phosphorylation at this site could not be confirmed in vivo.

Disease relevance. A chromosomal aberration involving ZFYVE19 is associated with acute myeloblastic leukemia (AML). Translocation t(11;15)(q23;q14) with KMT2A/MLL1. Cholestasis, progressive familial intrahepatic, 9 (PFIC9) [MIM:619849] An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. PFIC9 onset is in infancy or early childhood. The disease is caused by variants affecting the gene represented in this entry. Some evidences point to Met-76 as the main translation initiation site. In this context, PFIC9-associated variant p.M76V can disrupt translation initiation.

Domain organisation. The FYVE-type zinc finger mediates binding to phosphatidylinositol-3-phosphate (PtdIns(3)P). The MIM1-B motif mediates interaction with VPS4A.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96K21-1	1	yes
Q96K21-2	2
Q96K21-3	3
Q96K21-4	4

RefSeq proteins (4): NP_001070736, NP_001245349, NP_001245350, NP_116239 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000306	Znf_FYVE	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017455	Znf_FYVE-rel	Domain
IPR044553	Bbox1_ANCHR	Domain

Pfam: PF01363, PF22586

UniProt features (39 total): sequence variant 9, binding site 8, modified residue 6, region of interest 3, splice variant 3, short sequence motif 2, chain 1, zinc finger region 1, site 1, cross-link 1, mutagenesis site 1, sequence conflict 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96K21-F1	69.82	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 145–146 (breakpoint for translocation to form kmt2a/mll1-zfyve19)

Ligand- & substrate-binding residues (8): 83; 96; 99; 104; 107; 125; 128; 80

Post-translational modifications (7): 144, 243, 293, 354, 463, 207, 286

Mutagenesis-validated functional residues (1):

Position	Phenotype
101	abolishes binding to phosphatidylinositol-3-phosphate (ptdins(3)p) without affecting localization to the midbody.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_MITOTIC_CYTOKINESIS, GOBP_NEGATIVE_REGULATION_OF_CELL_DIVISION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_CYTOKINETIC_PROCESS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_REGULATION_OF_CELL_CYCLE_G2_M_PHASE_TRANSITION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_CYTOKINESIS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, GOCC_CENTROSOME, GOBP_REGULATION_OF_CYTOKINESIS, GOBP_NEGATIVE_REGULATION_OF_MITOTIC_CELL_CYCLE

GO Biological Process (4): negative regulation of cytokinesis (GO:0032466), mitotic cytokinesis checkpoint signaling (GO:0044878), midbody abscission (GO:0061952), cell division (GO:0051301)

GO Molecular Function (5): zinc ion binding (GO:0008270), phosphatidylinositol-3-phosphate binding (GO:0032266), protein binding (GO:0005515), lipid binding (GO:0008289), metal ion binding (GO:0046872)

GO Cellular Component (6): centrosome (GO:0005813), midbody (GO:0030496), cleavage furrow (GO:0032154), Flemming body (GO:0090543), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	2
cytokinesis	1
negative regulation of cell cycle process	1
regulation of cytokinesis	1
negative regulation of cell division	1
mitotic cell cycle checkpoint signaling	1
negative regulation of G2/M transition of mitotic cell cycle	1
membrane organization	1
mitotic cytokinetic process	1
cellular process	1
transition metal ion binding	1
phosphatidylinositol phosphate binding	1
cation binding	1
centriole	1
microtubule organizing center	1
cell division site	1
plasma membrane region	1
midbody	1
intracellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1307 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZFYVE19	CHMP4C	Q96CF2	740
ZFYVE19	DNAJC17	Q9NVM6	527
ZFYVE19	LRRC57	Q8N9N7	520
ZFYVE19	CHMP6	Q96FZ7	519
ZFYVE19	IST1	P53990	518
ZFYVE19	CT45A2	Q5DJT8	506
ZFYVE19	PUS7L	Q9H0K6	504
ZFYVE19	VPS25	Q9BRG1	487
ZFYVE19	AURKB	Q96GD4	486
ZFYVE19	CHMP4A	Q9BY43	479
ZFYVE19	C15orf62	A8K5M9	475
ZFYVE19	CHMP2A	O43633	462
ZFYVE19	VWC2L	B2RUY7	450
ZFYVE19	ULK3	Q6PHR2	446
ZFYVE19	PABIR1	Q96E09	446

IntAct

56 interactions, top by confidence:

A	B	Type	Score
ZFYVE19	VPS4B	psi-mi:“MI:0915”(physical association)	0.780
VPS4B	ZFYVE19	psi-mi:“MI:0915”(physical association)	0.780
HTT	ZFYVE19	psi-mi:“MI:0915”(physical association)	0.740
ZFYVE19	HTT	psi-mi:“MI:0915”(physical association)	0.740
ZFYVE19	MITD1	psi-mi:“MI:0915”(physical association)	0.720
MITD1	ZFYVE19	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (62): ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), MITD1 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Affinity Capture-MS), ZFYVE19 (Co-fractionation), ZFYVE19 (Affinity Capture-MS), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Two-hybrid), ZFYVE19 (Affinity Capture-RNA)

ESM2 similar proteins: A1L131, A4IFK7, C5IJB0, D3ZND0, F1MX48, O60232, O95400, P35689, Q0VCT3, Q17QX2, Q2KIJ6, Q2YD98, Q3ZBK7, Q3ZBN4, Q4R4I0, Q53GS7, Q5EAN7, Q5FVK6, Q5PPF5, Q5RAS2, Q5T0F9, Q68F60, Q69ZT1, Q6AYI4, Q6NU18, Q6TLH3, Q7L4P6, Q7TMX5, Q8BL74, Q8BRN9, Q8BSI6, Q8C0R7, Q8C6D4, Q8N5A5, Q8R322, Q8VDM1, Q91VL8, Q91WA6, Q91WR3, Q969X0

Diamond homologs: A0JMD2, A1CEK1, A1DFP5, A2QWA2, A3LX75, A4QTV1, A8QCE4, B0G126, B0WAQ0, B3MT31, B3P851, B4G2G5, B4IC49, B4JHI7, B4K982, B4M140, B4NFJ7, B4PRU6, D2H5P6, D3ZVP7, D4A8G9, O13821, O14964, O76902, O88387, O95405, O96838, P0CS26, P0CS27, P34657, P34756, P40343, Q05B78, Q0CJV3, Q0P4S0, Q0U4Z8, Q0V8S0, Q0WUR5, Q13615, Q15075

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
midbody abscission	6	293.1×	2e-12
multivesicular body sorting pathway	5	267.5×	3e-10
multivesicular body assembly	6	210.7×	9e-12
protein transport	5	14.6×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	3
Uncertain significance	71
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
1686832	NM_001077268.2(ZFYVE19):c.314C>G (p.Ser105Ter)	Pathogenic
1686833	NM_001077268.2(ZFYVE19):c.226A>G (p.Met76Val)	Pathogenic
1686834	NM_001077268.2(ZFYVE19):c.514C>T (p.Arg172Ter)	Pathogenic
1686835	NM_001077268.2(ZFYVE19):c.547C>T (p.Arg183Ter)	Pathogenic
1686836	NM_001077268.2(ZFYVE19):c.379C>T (p.Gln127Ter)	Pathogenic
1686837	NM_001077268.2(ZFYVE19):c.667C>T (p.Arg223Ter)	Pathogenic
3036314	NM_001077268.2(ZFYVE19):c.1174C>T (p.Arg392Ter)	Likely pathogenic
3391294	NM_001077268.2(ZFYVE19):c.717+1G>T	Likely pathogenic
4845728	NM_001077268.2(ZFYVE19):c.122_123insGGGGCAGGGC (p.Glu46fs)	Likely pathogenic

SpliceAI

2229 predictions. Top by Δscore:

Variant	Effect	Δscore
15:40807365:TCA:T	donor_loss	1.0000
15:40807366:CA:C	donor_loss	1.0000
15:40807367:A:C	donor_loss	1.0000
15:40807368:C:CT	donor_loss	1.0000
15:40807368:CCT:C	donor_gain	1.0000
15:40809459:G:GG	donor_gain	1.0000
15:40809966:GCCCA:G	donor_gain	1.0000
15:40809971:G:GG	donor_gain	1.0000
15:40813321:A:AG	acceptor_gain	1.0000
15:40813321:AT:A	acceptor_gain	1.0000
15:40813322:T:G	acceptor_gain	1.0000
15:40813322:T:TA	acceptor_gain	1.0000
15:40813335:A:AG	acceptor_gain	1.0000
15:40813335:AAGT:A	acceptor_gain	1.0000
15:40813336:A:G	acceptor_gain	1.0000
15:40813336:AGT:A	acceptor_gain	1.0000
15:40813337:G:GA	acceptor_gain	1.0000
15:40813337:GT:G	acceptor_gain	1.0000
15:40813337:GTG:G	acceptor_gain	1.0000
15:40813337:GTGA:G	acceptor_gain	1.0000
15:40813337:GTGAC:G	acceptor_gain	1.0000
15:40813338:T:TA	acceptor_gain	1.0000
15:40813413:AGCAG:A	donor_loss	1.0000
15:40813414:GCAG:G	donor_gain	1.0000
15:40813414:GCAGG:G	donor_loss	1.0000
15:40813415:CAG:C	donor_loss	1.0000
15:40813416:AG:A	donor_loss	1.0000
15:40813417:GG:G	donor_loss	1.0000
15:40813418:GT:G	donor_loss	1.0000
15:40813419:T:G	donor_loss	1.0000

AlphaMissense

3042 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:40807848:T:C	F87L	0.998
15:40807850:C:A	F87L	0.998
15:40807850:C:G	F87L	0.998
15:40809212:T:C	C125R	0.996
15:40807849:T:C	F87S	0.994
15:40809149:T:C	C104R	0.994
15:40809221:T:A	C128S	0.994
15:40809222:G:C	C128S	0.994
15:40809125:T:C	C96R	0.993
15:40809212:T:A	C125S	0.993
15:40809213:G:C	C125S	0.993
15:40809221:T:C	C128R	0.993
15:40807827:T:C	C80R	0.992
15:40809125:T:A	C96S	0.992
15:40809126:G:C	C96S	0.992
15:40809213:G:A	C125Y	0.992
15:40807827:T:A	C80S	0.991
15:40807828:G:C	C80S	0.991
15:40809146:T:C	F103L	0.991
15:40809148:C:A	F103L	0.991
15:40809148:C:G	F103L	0.991
15:40809150:G:A	C104Y	0.991
15:40809158:T:C	C107R	0.991
15:40809149:T:A	C104S	0.990
15:40809150:G:C	C104S	0.990
15:40809158:T:A	C107S	0.990
15:40809159:G:C	C107S	0.990
15:40807849:T:G	F87C	0.989
15:40809151:T:G	C104W	0.989
15:40809210:T:A	V124D	0.989

dbSNP variants (sampled 300 via entrez): RS1000378083 (15:40815497 G>A,T), RS1000592597 (15:40813181 C>A,G,T), RS1000936706 (15:40807270 G>A,C), RS1001595906 (15:40814359 T>C), RS1002161752 (15:40808619 G>A,C), RS1002498243 (15:40812967 T>A), RS1002720465 (15:40807160 A>G), RS1002950783 (15:40809622 G>A), RS1003606553 (15:40811199 A>C), RS1003660750 (15:40805686 C>T), RS1003691661 (15:40805116 A>G,T), RS1003853592 (15:40807533 T>C), RS1004135443 (15:40806058 G>A), RS1004173019 (15:40811049 G>A), RS1004711344 (15:40812136 G>C)

Disease associations

OMIM: gene MIM:619635 | disease phenotypes: MIM:619849

GenCC curated gene-disease

Disease	Classification	Inheritance
cholestasis, progressive familial intrahepatic, 9	Strong	Autosomal recessive

Mondo (1): cholestasis, progressive familial intrahepatic, 9 (MONDO:0030800)

Orphanet (0):

HPO phenotypes

15 total (15 of 15 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000952	Jaundice
HP:0000989	Pruritus
HP:0001406	Intrahepatic cholestasis
HP:0001409	Portal hypertension
HP:0001413	Micronodular cirrhosis
HP:0001744	Splenomegaly
HP:0001945	Fever
HP:0002014	Diarrhea
HP:0002240	Hepatomegaly
HP:0003577	Congenital onset
HP:0003593	Infantile onset
HP:0006563	Malformation of the hepatic ductal plate
HP:0011463	Childhood onset
HP:0034328	Fibro-obliterative bile-duct lesion

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST008559_8	Anxiety and stress-related disorders	7.000000e-07
GCST010725_23	Malaria	2.000000e-06
GCST010725_38	Malaria	3.000000e-06
GCST010725_80	Malaria	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010098	stress-related disorder

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methacrylaldehyde	affects cotreatment, affects expression, increases expression, increases abundance	2
Acetaminophen	decreases expression, increases expression	2
Acrolein	increases expression, increases abundance, affects cotreatment, affects expression	2
Estradiol	decreases expression	2
Ozone	increases expression, increases abundance, affects cotreatment, affects expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
alpha-pinene	affects expression, increases abundance, affects cotreatment	1
beta-lapachone	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
Temozolomide	decreases expression	1
Air Pollutants	affects cotreatment, affects expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, decreases expression	1
Methyl Methanesulfonate	increases expression	1
Paraoxon	increases expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Valproic Acid	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.